Tsai, Donald E <br/><br/>
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody.  [electronic resource] 

 -  Clinical lymphoma  Jun 2003 
 - 56-9 p.  digital 
<br/><br/> Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1526-9655 
<br/><br/><label>Standard No.: </label>10.3816/clm.2003.n.015  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized<br/>Antigens, CD--immunology<br/>Antigens, CD20--immunology<br/>Antigens, Differentiation, B-Lymphocyte--immunology<br/>B-Lymphocytes--immunology<br/>Cell Adhesion Molecules<br/>Disease Progression<br/>Humans<br/>Lectins--immunology<br/>Lymphoma, Non-Hodgkin--immunology<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--immunology<br/>Radioimmunotherapy--methods<br/>Radiopharmaceuticals<br/>Sialic Acid Binding Ig-like Lectin 2<br/>Treatment Outcome<br/>Yttrium Radioisotopes--therapeutic use